South Korea FDA Accused Of Lax Monitoring Of Sibutramine Drugs
This article was originally published in PharmAsia News
Executive Summary
South Korea's FDA is being criticized for being lax in its regulation of the weight-loss drug sibutramine, now banned in the United States, Europe and other markets
You may also be interested in...
Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says
Updated draft guidance on promotion of biologic reference products, biosimilars and interchangeable biosimilars offers another indication of the US’s push to do away with the interchangeability designation.
Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time
Small sterilizers told Medtech Insight that they were ready for the EPA’s controversial EtO emissions rule, while community advocates expressed concerns.
Day One Springs Into Commercial Action With Ojemda Approval
The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.